Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Despite these developments, Humana's stock performance remained flat over the past week. During the same period, broader markets saw gains, bolstered by strong earnings from major tech companies.

The company's recent financial performance has been mixed. While Humana has maintained a solid ... HUM appears on our undervalued or overvalued stock lists. These tools provide a clearer picture ...

Humana Inc.’s stock was up 2% Friday after three straight sessions of declines, but investors paying attention to the performance of its bonds on Thursday may have had something of a heads-up on ...

Sarah James, a stock analyst with Cantor Fitzgerald ... The lower rating won’t affect Humana’s performance until 2026, but the company said it was “disappointed with its performance and ...

Furthermore, Humana continues to face pressure from rising medical costs, and its benefits expense ratio increased by 270 bps y-o-y to 89%, weighing on its stock performance. Our detailed analysis ...

Humana stock closed at $246.49 ... The company said it also is focused on improving its performance to regain its star rating. Humana, one of the biggest providers of Medicare Advantage coverage ...

The company said it is disappointed in its performance ... “Humana Plunges as Medicare Quality Rating Drop Threatens Revenue.” Watch These UnitedHealth Price Levels as Stock Extends Slide ...

Humana (HUM) stock is plunging in Wednesday's session ... Sign up "The decline in Stars performance for 2025 will impact Humana's quality bonus payments in 2026," Humana said in the filing.

Shares of Humana Inc. were suffering another beating ... insurer’s large Medicare Advantage plans because it missed some performance measures. Based on preliminary 2025 data from the Centers ...